Archive for August, 2021

Until this week, Aubrey de Grey was best known as the longevity researcher who predicted the first human to live 1,000 years may already be alive. Now, de Grey stands accused of being a sexual predator.

Celine Halioua, who received research funding from de Greys SENS Research Foundation, set out her accusations in a blog post titled Aubrey de Grey is a sexual predator. Laura Deming, founder of life extension VC shop The Longevity Fund, set out separate allegations against de Grey in her own blog post.

Deming wrote: I had one bad experience with him when I was 17he told me in writing that he had an adventurous love life and that it had always felt quite jarring not to let conversations with me stray in that direction given that [he] could treat [me] as an equal on every other level. He sent this from his work email, and Id known him since I was 14.

At the time, Deming said she wrote it off as a mistake. However, in the past few months, in part through conversations with Celine Halioua, Deming has come to believe her experience is part of a serial pattern hes enacted with women over whom hes in a position of power.

The accusations made by Halioua center on a dinner at which she was sat next to de Grey by a SENS executive. I was told to keep him entertained; Aubrey funneled me alcohol and hit on me the entire night. He told me that I was a glorious woman and that as a glorious woman I had a responsibility to have sex with the SENS donors in attendance so they would give money to him, Halioua wrote.

Halioua left that dinner sobbing and said it has taken her years to shake the deep-seated belief that I only got to where I am due to older men wanting to have sex with me. In the post, Halioua accused an unnamed SENS executive of harassing her so severely that she eventually dropped out of my PhD to escape him. Halioua is now CEO of a biotech startup developing drugs to extend dog life span.

De Grey responded to the accusations in a Facebook post. The longevity researcher admitted he inadvisedly wrote the email discussed by Deming and unreservedly regrets having done so. In all other regards, de Grey denies the accusations, which he framed as a setup.

I'm putting it out there right now: if other accusers come forward with supporting evidence, I will step aside a great deal faster than Cuomo just did. But if they don't who's the real culprit here? Hint: in my ever-so-personal view, it's not Celine or Laura. The unequivocally clear conclusion that I draw from the above is that they have been set up, de Grey wrote.

De Grey believes people have deceived Deming and Halioua into the view that I have done many things that I have in fact not done. As to who would orchestrate such a deception and why, de Grey said: I have been vigorously advised to keep my counsel on that question for another day or two but, as they say, watch this space.

SENS has put de Grey on administrative leave. An independent investigation into the allegations, which SENS first learned of in late June, is now underway.

Read more:
Leading longevity researcher accused of sexual harassment - FierceBiotech

WASHINGTON The U.S. Missile Defense Agency is examining the possibility of building a layered ballistic missile defense architecture for the homeland that would bolster the current ground-based system in Alaska, all while a next-generation capability is developed and fielded.

The MDA featured its plan in its fiscal 2021 budget request, but there isnt much of a strategy laid out in its fiscal 2022 funding picture. And so lawmakers want answers before turning on the funding spigot.

Developing such an architecture, even though it would use mostly proven systems, has many hurdles, as MDA Director Vice Adm. Jon Hill said last year.

The plan would include establishing layers of defensive capability relying on the Aegis Weapon System, particularly the SM-3 Block IIA missiles used in the system, and a possible Aegis Ashore system in Hawaii. The underlay would also include the Terminal High Altitude Area Defense system.

The layered approach would buy time while the Pentagon scrambles to field a new interceptor to replace older Ground-Based Interceptors after canceling its effort to redesign the kill vehicle for the GBIs in its Ground-based Midcourse Defense system located at Fort Greely, Alaska, and Vandenberg Space Force Base, California.

The test stressed the system, putting it up against a long-range intercontinental ballistic missile, but the MDA wants to conduct another yet-to-be-scheduled test against a more complex ICBM target with separation debris and countermeasures.

However, the validation of a possible underlay doesnt stop with a few tests. Upgrades will be required based on threats; combat system certifications will need to be conducted; and work must be performed with the Navy to determine where Aegis ships should deploy, Hill said. The agency will also have to determine how quickly it can ramp up its production line for SM-3 Block IIA missiles.

Sign up for our Early Bird Brief Get the defense industry's most comprehensive news and information straight to your inbox

Subscribe

Enter a valid email address (please select a country) United States United Kingdom Afghanistan Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, The Democratic Republic of The Cook Islands Costa Rica Cote D'ivoire Croatia Cuba Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guinea Guinea-bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Israel Italy Jamaica Japan Jordan Kazakhstan Kenya Kiribati Korea, Democratic People's Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, The Former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia, Federated States of Moldova, Republic of Monaco Mongolia Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory, Occupied Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and The Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia and Montenegro Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and The South Sandwich Islands Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan, Province of China Tajikistan Tanzania, United Republic of Thailand Timor-leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States United States Minor Outlying Islands Uruguay Uzbekistan Vanuatu Venezuela Viet Nam Virgin Islands, British Virgin Islands, U.S. Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe

Thanks for signing up!

By giving us your email, you are opting in to the Early Bird Brief.

Hill said last fall that if the agency succeeds with Aegis, it could go down the path with THAAD, then work on engagement coordination between layers.

When the FY22 budget request came out at the end of May, Hill said funding would focus on looking at how the Command and Control, Battle Management, and Communications system could incorporate Aegis and THAAD capabilities for the homeland, and how those systems would be linked to give options to combatant commanders.

But, he added, those decision have not been made to date.

When asked if the agency was cooling on a layered homeland defense, Hill said: I wouldnt say its no longer a priority since we do have investment in the budget, but there are some very serious policy implications, and so we want to make sure that we get the policy angles right.

The agency also wants to make sure its still a need for U.S. Northern Command in light of a now-established service life extension program for the GMDs Ground-Based Interceptors already emplaced, Hill noted. The command did not include layered homeland defense in its list of unfunded requirements sent to Congress in June.

The big concern, back when layered homeland defense was first discussed, was the concern that the existing fleet would start to lose its reliability over time while we also had this timeline for the Next-Generation Interceptor off to the right, Hill said.

Plans for the Next-Generation Interceptor are moving forward with a competition between Lockheed Martin and Northrop Grumman, and theres talk the timeline for first emplacement could be earlier than anticipated.

Yet, Congress is getting impatient over a lack of answers regarding progress toward an architecture that could shore up any gap in capability now and into the future.

During a June 14 hearing with the House Armed Services Committees strategic forces subpanel, Rep. Elise Stefanik, R-N.Y., asked for an update on the report on the layered homeland defense system, which was required in the FY21 National Defense Authorization Act. She noted that the deadline of March 1, 2021, had passed.

Hill responded that, while there are no technical barriers to an underlay, its really a policy question that we need to come through.

Without offering a timeline for delivering a report to Congress, Leonor Tomero, the Pentagons assistant secretary of defense for nuclear and missile defense policy, said at the same hearing: I can assure you that we are looking at what investments we make for a layered homeland defense, what priorities are the subject of studies again in consultation with the Missile Defense Agency and the Office of Cost Assessment and Program Evaluation.

The Defense Department made an initial investment in FY22, Tomero added, and studies will inform further investments in FY23.

The Strategic Forces Subcommittee followed up in its markup of the FY22 authorization bill with a renewed push for a detailed report. The committee would direct the Pentagon to submit a report by the end of 2021 on development and deployment plans for using Aegis with SM-3 Block IIA interceptors as part of a layered missile defense system.

The report should include how Fort Drum, New York, previously identified as an East Coast location for Ground-Based Interceptors, might be used for future layered defense. Stefaniks district includes Fort Drum.

An analysis of how deploying Arleigh Burke-class guided-missile destroyers for homeland defense would affect Navy readiness and global force management would also be required, and the report should contain an applicable manning strategy should land-based Aegis systems be deployed as part of the architecture.

The House Appropriations Committees defense subpanel, in its markup of the FY22 spending bill, took hacks at Defense Department funding applied to the layered homeland defense totaling $203.7 million.

The committee zeroed out Aegis BMD layered homeland missile defense development, cutting all $98.96 million for which the MDA had budgeted, and a total of $64.56 million to work on similar development for THAAD.

According to the MDAs FY22 budget justification documents, the plan for developing Aegis for homeland defense includes refining system-level requirements and development to expand threat and mission space and to increase performance against moderate threats.

The committee noted the funding cut is due to a lack of validated requirements and acquisition strategy.

The Senate Armed Services Committee released a summary of its FY22 authorization bill, but aside from supporting the MDAs pursuit of the NGI, there is nothing else signaling its intentions.

The Senate Appropriations Committees defense subpanel has yet to release its markup of the FY22 spending bill as of press time on Aug. 2.

Software and hardware improvements needed to evolve both THAAD and Aegis systems, will be important to proceed irrespective of whether or not they end up deployed to support a thick defense of the continental United States, Tom Karako, senior fellow with the International Security Program and the direct of the Missile Defense Project at the Center for Strategic and International Studies told Defense News.

The non-recurring engineering planned for the layered defense program elements would be very useful to complete to support regional applications, he added. These systems began as regional defenses, and their continued evolution will benefit regional protection, such as for bases in Guam, Japan, and the like.

See the original post here:
How will the Pentagon close the homeland missile defense gap? - DefenseNews.com

VIDEO ABOVE: Jane Tiller discusses privacy issues surrounding online DNA tests. Watch full ep. here.

Karenne uploaded the data she received from her DNA test to a third party website. Her intention was to find out whether there were any hereditary medical issues in her family.

The very first thing that popped up was two BRCA genes, she told Insight. Which scared me quite considerably.

BRCA is an abbreviation for BReast CAncer gene. BRCA1 and BRCA2 are two different genes that have been found to impact a persons chances of developing breast cancer.

The first course of action for Karenne was to book an appointment with her doctor to talk through her genetic testing discovery. She wanted to get her doctors advice and find out if there was an option for further tests. My doctor pretty much said that it's too hard to be able to test the genes.

But Karenne decided to send her DNA to another direct consumer site for genetic health testing. The results came back with a different cancer gene.

Instead of just affecting breasts, it affects colon, bowel, breast, brain, skin, thyroid, there's a lot more to be concerned about.

After seeing a genetic counsellor Karenne did a colonoscopy at the age of 47. She discovered that she had polyps that may have been on the verge of becoming cancerous.

So by the time I turned 50 I would have already been fighting colon cancer.

Jane Tiller is an ethical, legal and social adviser in public health genomics at Monash University. She said there are few things people need to consider when they do genetic testing through a third party website. Privacy is one of them, she explained, adding that consumers dont know where their data will be sent and who will have access to it.

...People were given risk information that was actually inaccurate.

I think people don't always realise when they check a box to say yes, we'd like this to go to research that it's actually going to a pharmaceutical company for profit rather than maybe to a hospital for cancer research, she told Insight.

We don't always know which companies have those relationships and which don't, certainly in the terms and conditions they should say whether they'll share the data with third parties, whether they'll see your consent for it or not. Most people we know don't read terms and conditions.

Tiller said people also need to make sure the company theyre sending their data to for testing is a reputable company and that they receive accurate information.

A few years ago there was a study where they tried to validate results from interpretation websites and about 40 per cent of results were found to be false positives. People were given risk information that was actually inaccurate.

When you are not going through a clinically accredited genetic test you dont know whether the information you are getting back is accurate or not and whether you should be making decisions based on that.

Karenne is glad she did the test. She is now 50 years old and gets regular colonoscopies. She wants to get to the forefront of any health complication that may emerge. Due to her BRACA genes, (which had mutated increasing the risk of breast cancer) Karenne also underwent a double mastectomy in early 2021.

Im fully recovered now and more relieved and one less thing to worry about.

The rest is here:
How a genetic test led this woman to get a double mastectomy - SBS

FREMONT, Calif., Aug. 12, 2021 /PRNewswire/ -- The premium market intelligence report published by BIS Research on the title Global Direct-to-Consumer Genetic Testing Markethighlights that the market is projected to reach $6.60 billion by 2031. The study also highlights that the market is set to witness a CAGR of 17.30% during the period 2021-2031. The growth of the market is aided by rising government initiatives for the implementation of large sequencing initiatives coupled with the increasing requirement of genetic testing, including the current COVID-19 pandemic.

The global direct-to-consumer (DTC) genetic testing market consists of companies providing genetic testing services without the involvement of healthcare professionals. The DTC genetic testing companies offer genetics testing services for ancestry, health and wellness, and entertainment. Recent trends regarding extensive funding from various investors for the promotion of genetic testing are significantly propelling the market. Also, owing to the emerging concept of consumer empowerment, the global direct-to-consumer genetic testing market is witnessing a massive influx of new entrants in the industry.

Browse 04 Market Data Tables and 104 Figures spread through 187 Pages and in-depth TOC of the Global Direct-to-Consumer Genetic Testing Market Analysis and Forecast, 2021-2031.

The comprehensive study of the global direct-to-consumer genetic testingmarket by BIS Research covers the following:

Who should buy this report?

View the Report from BIS Research: Global Direct-to-Consumer Genetic Testing Market

To gain a holistic view of the market, data from different segments of the market has been analyzed minutely. These segments include technology, business channel, product type, market share analysis, growth share analysis, and region. Each of these segments is further categorized into sub-segments and micro-segments to compile an in-depth study.

The premium market intelligence by BIS Research additionally throws a spotlight on the opportunities existing in the market, including the higher adoption of genetic tests for early diagnosis of various chronic conditions such as cancer, prenatal screening, and infectious diseases, and increasing awareness among consumers regarding preventive healthcare.

The business channel and product analysis of the global market includes data analysis on the satisfaction level of different kits and services offered by the leading and emerging companies. The study is majorly centered on the sub-segments and micro-segments of the different product markets, such as ancestry, health and wellness, and entertainment.

To emphasize the dominance of the single nucleotide segment over whole genome sequencing under the technology category of direct-to-consumer genetic testing market in 2020 and 2031, Nitish Kumar Singh, Principal Analyst, BIS Research, states, "The reason for market growth can be attributed to the large-scale research and development along with several sequencing initiatives taken globally. The increasing disease burden, including the current COVID-19 pandemic, has led to large capital investments by key players along with the conscious efforts of the manufacturers to ensure data safety and quality of the results obtained after the test."

Request for a Sample: https://bisresearch.com/requestsample?id=1155&type=download

Key insights are drawn from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The key players profiled in the report include 23andme, Inc., Ancestry.com LLC, 24Genetics, Atlas Biomed, Color Genomics, DNAfit, Gene by Gene, 10.9 Chengdu Twenty-Three Rubik's Cube Biotechnology Co., Ltd., Easy DNA, Mapmygenome, Laboratory Corporation of American Holdings, Myriad Genetics, Inc., Konika Minolta, Inc., and XCODE Lifescience, Inc.

The study also offers strategic recommendations that can help organizations track various products, trends, and technologies that are changing the market dynamics. The recommendations by BIS Research also offer bespoke research services to help organizations meet their objectives.

How can market intelligence on direct-to-consumer genetic test add value to an organization's decision-making process?

Insightful Questions Covered to Enable Companies take Strategic Decisions

Related Reports:

Global Molecular Diagnostics Point of Care Market - Analysis and Forecast, 2019-2029

Global Molecular Diagnostics Market Analysis and Forecast, 2018-2028

Global Single-Cell-Sequencing Market Analysis and Forecast, 2018-2029

About BIS Research:

BIS Research, a premium market intelligence company, offers in-depth insights and consulting to Fortune 500 companies. We are established and known for tracking the growth of deep technologies across key industry verticals and the subsequent challenges and opportunities associated with deep tech across markets, applications, and products.

With more than 1,000 clients, over 10,000 plus primary interviews, and approximately 200 reports published in a year, BIS Research has often been sighted for its ability to track emerging tech trends early on. We provide market estimations, analysis on emerging high-growth applications, technology analysis, highly segmented granular country-level market data, and other important market parameters that come in handy for our clients during strategic decision-making.

BIS Healthcare provides market-leading insights and data on lab-to-market and early-stage technologies such as precision medicine, robotics and imaging, life sciences and biopharma, and digital health. We have been celebrating the contribution of scientists, academicians, and industry researchers through our highly recognized compendiums Top 25 Voice, such as Healthcare Robotics, Precision Medicine, and Precision Medicine Asia.

Contact: Bhavya Banga Email: [emailprotected] BIS Research Inc. 39111 PASEO PADRE PKWY STE 313,FREMONT CA 94538-1686 Visit our Blog @ https://blog.bisresearch.com/Connect with us on LinkedIn @ https://www.linkedin.com/company/bis-research Connect with us on [emailprotected] https://twitter.com/BISResearch

SOURCE BIS Research

Visit link:
Global Direct-to-Consumer Genetic Testing Market to Reach $6.60 Billion by 2031, Says BIS Research Study - PRNewswire

Lyndsay Willmott, MD, discussesthe importance of genetic testing in ovarian cancer.

Lyndsay Willmott, MD, gynecologic oncologist, Arizona Oncology, discussesthe importance of genetic testing in ovarian cancer.

When treating patients withovarian cancer, genetic testing is one of the easiest tools to incorporateinto clinical practice to help guide treatment decisions, according to Willmott. However, becausegenetic counselors are scarcein some areas, it is importantto be an informed advocate for genetic testing so that its use is initiated in the frontline, Willmott says.Additionally,educating patients on the importance of genetic testing can serve to overcome hesitancy and empower them with respect to treatment decisions, Willmott adds.

Moreover, it has been shown that patients with a BRCA mutation may perform better with certain agents, according to Willmott. Although this might not be universal, it is important to counsel patients about the link between mutational status and their available treatment options,Willmott says.Sharing this information with patients will help them to manage expectations regarding their treatment journey and empower them through the clinical decisions that are being made, Willmott concludes.

Follow this link:
Dr. Willmott on the Importance of Genetic Testing in Ovarian Cancer - OncLive

New Jersey, United States,-The latest study on the industrial growth of the DTC Genetic Testing Market 2021-2028. A detailed study has been performed to provide the latest insight into the acute characteristics of the DTC Genetic Testing market. The report provides various market forecasts related to market size, revenue, production, CAGR, consumption, gross margin, price, and other critical factors. The report not only emphasizes the major driving and restraining forces in this market but also offers a comprehensive study of future trends and developments in the market. It also studies the roles of leading players in the industry market including their company overview, financial summary, and SWOT analysis.

This report analyzes the impact of the COVID-19 pandemic on market growth and sales. The report also includes an in-depth analysis of the current and future impact of the pandemic and post-COVID-19 scenario analysis.

Get | Download Sample Copy @ https://www.marketresearchintellect.com/download-sample/?rid=435683

The report provides a detailed analysis of the major market players along with an overview of their business, expansion plans, and strategies. The main actors examined in the report include:

DTC Genetic Testing Market: Key Catalysts

The market is further subdivided according to end-user type and application. The report also includes an assessment of the segment that is expected to be the market leader over the forecast years. The report provides detailed market segmentation by type and application along with historical data and forecast.

The report further studies the market segmentation based on the types of products offered in the market and their end-uses/uses.

While segmenting the Market by DTC Genetic Testing Types, the Report includes:

While segmenting the Market by DTC Genetic Testing Applications, the report covers the following application areas:

Ask for a Discount @ https://www.marketresearchintellect.com/ask-for-discount/?rid=435683

DTC Genetic Testing Market Report Scope

Due to the regional segmentation, the market is divided into the main regions North America, Europe, Asia-Pacific, Latin America, Middle East and Africa. In addition, the regional analysis covers the breakdown of the market and key players by country.

The research report offered by the Market Research Intellect provides an updated view of the global DTC Genetic Testing market. The report provides a detailed analysis of the key trends and emerging market factors that could affect the growth of the industry. Additionally, the report studies market features, competitive landscape, market size and growth, regional split, and strategies for this market.

DTC Genetic Testing Report Content Highlights:

DTC Genetic Testing World Market Review

Market competition from players and manufacturers

competitive environment

Production, estimate of sales by type and application

Regional analysis

Analysis of the industrial chain

Forecast of the world market DTC Genetic Testing

For more informative information, please visit us @ https://www.marketresearchintellect.com/product/global-dtc-genetic-testing-market-size-and-forecast/

Visualize DTC Genetic Testing Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment and Key players of your market. Present your Market Report & findings with inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize DTC Genetic Testing Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

Thank you for reading our report. The report can be customized based on chapters or regions. Contact us to learn more about customization options and our team will make sure you generate a report based on your needs.

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering customized and in-depth research studies.

Our advanced analytical research solutions, custom consulting and in-depth data analysis cover a range of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages. Etc

Our research studies help our clients to make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information without compromise.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi.Contact us:

Mr. Edwyne Fernandes

Market Research IntellectUS: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Website https://www.marketresearchintellect.com/

Read the original here:
DTC Genetic Testing Market Size, Analytical Overview, Growth and Forecast to 2028 - The Market Writeuo - The Market Writeuo

The Latest Released Preimplantation Genetic Testing Market study has evaluated the future growth potential of Global Preimplantation Genetic Testing market and provides information and useful stats on market structure and size. The report is intended to provide market intelligence and strategic insights to help decision makers take sound investment decisions and identify potential gaps and growth opportunities. Additionally, the report also identifies and analyses changing dynamics, emerging trends along with essential drivers, challenges, opportunities and restraints in Preimplantation Genetic Testing market. The study includes market share analysis and profiles of players such as Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology

If you are a Preimplantation Genetic Testing manufacturer and would like to check or understand policy and regulatory proposal, designing clear explanations of the stakes, potential winners and losers, and options for improvement then this article will help you understand the pattern with Impacting Trends.

Major Highlights of the Preimplantation Genetic Testing Market report released by Adroit Market Research

Market Breakdown by Applications: .

Market Breakdown by Types: by Test Type (Aneuploidy, Structural Chromosomal Abnormalities, Single Gene Disorders, X-linked Disorders, HLA Typing, Gender Identification) and Technology (Next Generation Sequencing, Polymerase Chain Reaction, Fluorescent In-Situ Hybridization, Comparative Genomic Hybridization, Single Nucleotide Polymorphism)

Revenue and Sales Estimation Historical Revenue and sales volume is presented and further data is triangulated with top-down and bottom-up approaches to forecast complete market size and to estimate forecast numbers for key regions covered in the report along with classified and well recognized Types and end-use industry.

SWOT Analysis on Preimplantation Genetic Testing Players

In additional Market Share analysis of players, in-depth profiling, product/service and business overview, the study also concentrates on BCG matrix, heat map analysis, FPNV positioning along with SWOT analysis to better correlate market competitiveness.

Demand from top notch companies and government agencies are expected to rise as they seek more information on latest scenario. Check Demand Determinants section for more information.

Regulation Analysis

Local System and Other Regulation: Regional variations in Laws for the use of Preimplantation Genetic Testing

Regulation and its Implications

Other Compliances

FIVE FORCES & PESTLE ANALYSIS:

In order to better understand Preimplantation Genetic Testing Market condition five forces analysis is conducted that includes Bargaining power of buyers, Bargaining power of suppliers, Threat of new entrants, Threat of substitutes, Threat of rivalry.

Political (Political policy and stability as well as trade, fiscal and taxation policies)

Economical (Interest rates, employment or unemployment rates, raw material costs and foreign exchange rates)

Social (Changing family demographics, education levels, cultural trends, attitude changes and changes in lifestyles)

Technological (Changes in digital or mobile technology, automation, research and development)

Legal (Employment legislation, consumer law, health and safety, international as well as trade regulation and restrictions)

Environmental (Climate, recycling procedures, carbon footprint, waste disposal and sustainability)

Heat map Analysis, 3-Year Financial and Detailed Company Profiles of Key & Emerging Players:Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer, Inc., CooperSurgical, Inc., Beijing Genomics Institute (BGI), Abbott Laboratories, Natera, Inc., Genea Limited, Rubicon Genomics, Inc. and Oxford Gene Technology

Geographically, the following regions together with the listed national/local markets are fully investigated:

APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

North America (U.S., Canada, and Mexico)

South America (Brazil, Chile, Argentina, Rest of South America)

MEA (Saudi Arabia, UAE, South Africa)

Global Preimplantation Genetic Testing Market Size (Sales) Market Share by Type (Product Category) [, Lifetime Preimplantation Genetic Testing, Regular Preimplantation Genetic Testing, Union Preimplantation Genetic Testing & Variable Preimplantation Genetic Testing] in 2020

Preimplantation Genetic Testing Market by Application/End Users []

Global Preimplantation Genetic Testing Sales and Growth Rate (2015-2028)

Preimplantation Genetic Testing Competition by Players/Suppliers, Region, Type and Application

Preimplantation Genetic Testing (Volume, Value and Sales Price) table defined for each geographic region defined.

Supply Chain, Sourcing Strategy and Downstream Buyers, Industrial Chain Analysis

..and view more in complete table of Contents

About Us

Adroit Market Research is an India-based business analytics and consulting company incorporated in 2018. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us:

Ryan Johnson

Account Manager Global

3131 McKinney Ave Ste 600, Dallas,

TX75204, U.S.A.

More:
Dissecting Growth Strategies for Preimplantation Genetic Testing Market by Thermo Fisher Scientific, Inc., Agilent Technologies, Inc., PerkinElmer -...

New Jersey, United States,-Verified Market Research recently released a new report titled DTC Genetic Testing MarketSize Report, Growth and Forecast 2021-2028, Breakdown Data by Company, Key Regions, Types and Applications. The report has been compiled using primary and secondary research methodology that will provide a precise and precise understanding of the DTC Genetic Testing market. Analysts used a top-down and bottom-up approach to assess the segments and properly assess their impact on the DTC Genetic Testing market. The report offers a market overview which briefly describes the market situation and major segments. It also mentions the best players represented in the DTC Genetic Testing market.

The 2021 report offers an in-depth analysis of each sector of this DTC Genetic Testing industry. Fill in historical DTC Genetic Testing data according to customer requirements. It offers DTC Genetic Testing market research globally and locally. The detailed segment and manufacturer information of DTC Genetic Testing helps guide future benefits and make important decisions for the growth of DTC Genetic Testing.

Get | Download Sample Copy with TOC, Graphs & List of Figures @https://www.verifiedmarketresearch.com/download-sample/?rid=12309

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Full Genomes Corporation Quest Diagnostics, Myriad Womens Health Inc., Gene By Gene, Ltd., Positive Biosciences Ltd., 23andMe, Inc.

DTC Genetic Testing Market Segmentation

DTC Genetic Testing Market by Test Type

Carrier Testing Predictive Testing Nutrigenomic Testing Ancestry & Relationship Testing Others

DTC Genetic Testing Market by Technology

Targeted analysis Single nucleotide polymorphism (SNP) chips Whole genome sequencing (WGS)

In the next chapters, the research report reveals the development of the DTC Genetic Testing market segments. Analysts have segmented the market on the basis of product, application, end-users, and geography. Each segment of the DTC Genetic Testing market has been studied with in-depth insight. Analysts have evaluated the changing nature of the market segments, growing investments in manufacturing activities, and product innovation that are likely to impact them. In terms of geography, the report studies the changing political environment, social upliftment, and other government initiatives that are expected to contribute to the regional markets.

Get Discount On The Purchase Of This Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=12309

DTC Genetic Testing Market Report Scope

Geographic Segment Covered in the Report:

North America (USA and Canada) Europe (UK, Germany, France and the rest of Europe) Asia Pacific (China, Japan, India, and the rest of the Asia Pacific region) Latin America (Brazil, Mexico, and the rest of Latin America) Middle East and Africa (GCC and rest of the Middle East and Africa)

Key questions answered in the report:

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/dtc-genetic-testing-market/

Visualize DTC Genetic Testing Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize DTC Genetic Testing Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website:- https://www.verifiedmarketresearch.com/

Go here to read the rest:
DTC Genetic Testing Market Size By Type, Application Analysis, Key opportunities and challenges - The Market Writeuo - The Market Writeuo

As per the latest report by IMARC Group, titled Preimplantation Genetic Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026, the global preimplantation genetic testing market exhibited XX growth during 2015-2020. Looking forward, IMARC Group expects the market to grow at a CAGR of XX% during 2021-2026. Preimplantation genetic testing (PGT) detects abnormal embryos and facilitates the transfer of genetically normal embryos. It also reduces the trauma of several failed in vitro fertilization (IVF) cycles and early miscarriages. Moreover, PGT is used to treat individuals with high chances of having babies with specific genetic aberrations, as it protects children from inherited monogenic disorders. Apart from this, it is utilized in hematological disorders in children and in cases of advanced maternal age to prevent the birth of a syndromic child.

Request Free Sample Report: https://www.imarcgroup.com/preimplantation-genetic-testing-market/requestsample

We are regularly tracking the direct effect of COVID-19 on the market, along with the indirect influence of associated industries. These observations will be integrated into the report.

Preimplantation Genetic Testing Market Trends:

Rising birth rates and incidences of spontaneous miscarriages are some of the primary factors positively influencing the demand for PGT to minimize the need for multiple IVF cycles. Additionally, the growing risks of miscarriage with the womans age, along with the emerging trend of delayed parenthood is further strengthening the global market. Besides this, the expanding medical tourism sector and improving diagnostic modalities are also bolstering the market growth. Moreover, the introduction of innovative techniques, such as microarray and genome sequencing, coupled with the escalating demand for minimally invasive (MI) procedures, is positively influencing the market. Furthermore, the rising integration of PGT technology with Assisted Reproductive Technology (ART) procedures to offer improved outcomes to patients is expected to drive the global PGT market in the coming years.

Explore Full Report with TOC & List of Figure: https://bit.ly/3zUV5Wk

Key Market Segmentation:

Competitive Landscape:

The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.

Some of these key players include:

Breakup by Product:

Breakup by Procedure:

Breakup by Technology:

Breakup by Application:

Breakup by Region:

Key highlights of the Report:

Note: If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.

About Us

IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARCs information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the companys expertise.

Contact US

IMARC Group 30 N Gould St, Ste RSheridan, WY (Wyoming) 82801 USA Email: [emailprotected]Tel No:(D) +91 120 433 0800Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800

See original here:
Preimplantation Genetic Testing Market: Demand, Trends and Business Opportunities 2021-26 - The Market Writeuo - The Market Writeuo

Beverly Theil| Columnist

August is Child Support Awareness Month. Please be aware there are both dead beat moms as well as dead-beat dads. Lets look at how child support occurs.

More: ABOUT CHILDREN: It can't be said enough - have your children vaccinated

First, a relationship between the parent and child must be established. Maternity is established by the mother giving birth. Paternity is established several ways. If a couple is married at the time of a childs birth the husband is presumed to be the father. If the parents are not married, there is a voluntary acknowledgment process through completion of the Acknowledgment of Paternity Affidavit."

This form can be completed at the hospital when the child is born, before both parents leave the hospital, or it can be completed at your county's Child Support Enforcement Agency (CSEA) or your local Vital Statistics Registrar.

If the paternity of a child is contested or in doubt either parent may request the CSEA conduct DNAtesting to determine paternity. All parties are ordered to submit to genetic testing.

An administrative paternity order is issued based on the outcome of the genetic test, which must show at least a 99% probability of fatherhood. If either parent fails to submit to the test, or fails to submit the child for genetic testing, the CSEA may request the court to find the party in contempt and force compliance.

After paternity is established the CSEA schedules a support hearing to establish a support order for the child. Establishment of paternity refers to the legal determination of parentage, not the childs last name.

If the mother has given the child her last name and the father wants the child to have his last name but they do not agree, the father must go to court to have the name changed.

The process to establish paternity is available at any time before the child becomes 23 years old. Paternity can be established even if the parents live in different states or different countries.

A person may receive support if they are the child's biological parent, guardian, legal custodian or other person with whom the child lives. Support orders can sometimes be established by the CSEA without going to court but, if necessary, the CSEA will assist in obtaining a child support order.

The amount of support is determined by using the Ohio Child Support Guidelines. Both parents must provide verification of their incomes for the past six months or their most recent income tax returns. If the obligor (parent who owes support) doesnt pay the state may use income withholding.

This applies to not just wages and includes, but is not limited to: personal earnings; workers' compensation payments; unemployment compensation benefits; pensions; annuities; allowances; private or governmental retirement benefits; disability or sick pay; insurance proceeds; lottery prize awards; any form of trust fund or endowment; lump-sum payments; assets in a financial institution; any other payment in money.

They also can use the Tax Offset, the collection of state and federal tax refunds. Also they can report the support debt to the credit bureaus, invoke professional license suspension, increase the amount of income withholding to pay arrears; and get a seek work orderfor the parent.

Failure to comply with a child support order can result in contempt of court charges. Penalties can increase and include fines and/or jail time. Federal law provides for criminal non-support charges.

In certain cases that includes imprisonment for up to six months and/or a fine, and mandatory restitution of the unpaid support.

Be a good parent. Pay your child support.

Beverly Theil is a child advocate who lives in Ohio. She can be contacted at BeverlyVT@aol.com.

See more here:
ABOUT CHILDREN: A look at how child support works and the Child Support Enforcement Agency - Wooster Daily Record

The Hill may be compensated and/or receive an affiliate commission if you buy through our links.

Many of us have been spending more time than ever with our pets during the past year of stay-at-home lifestyles, and perhaps, by now, you've become just as curious about your dog as he seems to be about, well, everything.

We've got you covered in those efforts to discover more about what makes your furry friend special, along with ways to ensure they're living their best life possible. The All-in-One DNA My Dog Breed Identification Test & Dog Training Bundle is a comprehensive package primed to create better pet owners and happier animals.

Typically priced at more than $1,200, a limited-time discount currently drops that cost to only $59.99. The value has never been higher for this unique bundle.

To begin, the DNA My Dog Breed Identification Test is an at-home genetics test that requires only a simple mail-in process. This innovative kit will help you learn all about your pup's breed, health tendencies, natural traits, and unique habits.

Not only is this an easy way to uncover cool facts about your pet, but it's also an important step toward ensuring they experience a long, fulfilling life. This report includes a breakdown of breed composition, behavioral insights, hereditary health risks and potential links, and helpful suggestions.

This process is proven and earned recognition among Leaders in Ethical Canine Genetic Testing at the 2020 GHP Biotechnology Awards. And don't worryyour buddy won't need to deal with any pain along the way.

All that's necessary is a gentle swab, which is then sent back in a prepaid envelope. Soon afterward, a detailed report will be returned to you.

With this bundle, you will also gain unlimited access to eight courses that span 12 total hours. These easy-to-use educational guides detail need-to-know information on diets, leash use, and behavior.

You'll also gain insight into starting and sustaining a successful dog training business that benefits both you and any potential list of clients. Plus, discover the leading methods to raising a healthy, happy, and obedient puppy.

Take advantage of this deal and get to know your dog in greater detail than you've ever imagined by purchasing The All-in-One DNA My Dog Breed Identification Test & Dog Training Bundle for only $59.99 (reg. $1,239).

Prices subject to change.

View post:
Improve your dog's health and training with this low-cost bundle | TheHill - The Hill

CLEVELAND There is promising new research out of Cleveland thats giving hope to people around the world who are facing a terrifying future.

Jesse Lis lost her dad, Michael, in April of 2020. He was 64.

More painful, she says, was watching him die for more than a decade from Huntingtons Disease.

It is so scary to watch someone who was so perfect your whole life to deteriorate to nothing, to someone who's unable to walk, talk or even reason, said Lis. That's a really hard blow.

Another heavy blow is realizing it'll happen to you, too.

Huntingtons Disease is a fatal, progressive brain disease often described as having ALS, Parkinson's and Alzheimer's all at the same time.

It is genetic. A child of a parent with Huntingtons has a 50/50 chance of inheriting the faulty gene. Jesse and her family did genetic testing after her fathers diagnosis in 2008 and discovered the disease was pervasive in their family tree.

Jesse has it and knows the cruel fate that awaits. She is 40 years oldin the prime of her life right when it usually hits.

Every day I wake up and think, 'Is today the day that I'm going to trip and fall?' or 'Is today the day where I won't remember something really important?'"

It is a lot to cope with, but Jesse fights to stay positive and works hard to raise money and awareness as the president of the Northeast Ohio chapter of the Huntingtons Disease Society.

I am one of those people who isn't going to stop until I can save others and until I can save my family, she said.

Right now, there is no treatment to prevent or slow Huntingtons Disease, but new research at Case Western Reserve University could help change that.

This really surprised us when we saw the data, said Dr. Xin Qi.

Xin Qi and her team just discovered a potential breakthrough in how to prevent and slow the neuron degeneration that causes Huntingtons disease. She says this treatment is safer and more targeted than previous therapies. It is early, she cautions and says more research and clinical trials are still needed.

If our strategy demonstrates to be useful and safe to patients, I will say best of luck, within five years we may make some breakthrough, she said.

With an estimated 41,000 Americans being symptomatic, and 200,000 at-risk of inheriting Huntingtons, according to the Huntington Disease Society, the findings offer hope that families like Jesses are desperate for.

Its not fair that a fatal brain diagnosis should impact every generation, she said. It's just not fair.

You are invited to help these families. The Team Hope Walk is Sunday, Aug. 15 at the Cleveland Metroparks Zoo. Registration starts at 7 a.m. The 5k starts at 8:30 a.m. and the walk starts at 9 a.m.

The money raised helps pay for social workers for families and also helps fund research for a cure and treatments.

Click here for more info.

Download the News 5 Cleveland app now for more stories from us, plus alerts on major news, the latest weather forecast, traffic information and much more. Download now on your Apple device here, and your Android device here.

You can also catch News 5 Cleveland on Roku, Apple TV, Amazon Fire TV, YouTube TV, DIRECTV NOW, Hulu Live and more. We're also on Amazon Alexa devices. Learn more about our streaming options here.

Read more:
How a local woman continues to fight despite a grim prognosis, and the promising research to cure Huntington's Disease - News 5 Cleveland

Request Download SampleAsk For DiscountCompany Profile

New Jersey, USA,"Global Breast Cancer Predictive Genetic Testing Market Analysis to 2028" is a professional and in-depth industry study with a particular focus on analyzing global market trends. The report aims to provide an overview of the next-generation clinical sequencing market with detailed market segmentation by type, application, and region. The report provides key statistics on the market status of key Breast Cancer Predictive Genetic Testing market players and provides key trends and opportunities in the market.

In addition, the global Breast Cancer Predictive Genetic Testing Market is expected to grow at a CAGR of about XX % over the next five years, will reach XX Billion US $in 2020, XX Billion US $in 2028

Get | Download Sample Copy with TOC, Graphs & List of Figures @https://www.marketresearchintellect.com/download-sample/?rid=230278

Competitor Analysis

The competitive landscape is an important aspect that every key player should be familiar with. The report throws light on the competitive scenario of the global Breast Cancer Predictive Genetic Testing market to know the competition at both domestic and global levels. Market experts also provide an overview of all the leading players of the global Breast Cancer Predictive Genetic Testing market, considering key aspects such as local operations, production, and product portfolio. In addition, the company's report is based on research key factors such as the company's size, market share, market growth, income, output, and profit.

The research focuses on the current market size of the Breast Cancer Predictive Genetic Testing market and its growth rates based on records with the company outlines of key players/manufacturers:

The major players covered in Breast Cancer Predictive Genetic Testing Markets:

Market segmentation of Breast Cancer Predictive Genetic Testing market:

Breast Cancer Predictive Genetic Testing market is divided by type and application. For the period 2021-2028, cross-segment growth provides accurate calculations and forecasts of sales by Type and Application in terms of volume and value. This analysis can help you grow your business by targeting qualified niche markets.

Breast Cancer Predictive Genetic Testing Market breakdown by Type:

Breast Cancer Predictive Genetic Testing Market breakdown by application:

Get Discount On The Purchase Of This Report@https://www.marketresearchintellect.com/ask-for-discount/?rid=230278

Breast Cancer Predictive Genetic Testing Market Report Scope

Regional market analysis Breast Cancer Predictive Genetic Testing can be represented as follows:

Each regional Breast Cancer Predictive Genetic Testing sectors is carefully studied to understand its current and future growth scenarios. This helps players to strengthen their position. Use market research to get a better perspective and understanding of the market and target audience and ensure you stay ahead of the competition.

The base of geography, the world market of Breast Cancer Predictive Genetic Testing has segmented as follows:

For More Information or Query or Customization Before Buying, Visit @https://www.marketresearchintellect.com/product/global-breast-cancer-predictive-genetic-testing-market-size-and-forecast/

Visualize Breast Cancer Predictive Genetic Testing Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform to tell the story of this market. VMI provides in-depth predictive trends and accurate insights into more than 20,000 emerging and niche markets to help you make key revenue impact decisions for a brilliant future.

VMI provides a comprehensive overview and global competitive landscape of regions, countries, and segments, as well as key players in your market. Showcase your market reports and findings with built-in presentation capabilities, providing more than 70% of time and resources for investors, sales and marketing, R & D, and product development. VMI supports data delivery in Excel and interactive PDF formats and provides more than 15 key market indicators for your market.

Visualize Breast Cancer Predictive Genetic Testing Market using VMI @hhttps://www.marketresearchintellect.com/mri-intelligence/

The study explores in depth the profiles of the main market players and their main financial aspects. This comprehensive business analyst report is useful for all existing and new entrants as they design their business strategies. This report covers production, revenue, market share and growth rate of the Breast Cancer Predictive Genetic Testing market for each key company, and covers breakdown data (production, consumption, revenue and market share) by regions, type and applications. Breast Cancer Predictive Genetic Testing historical breakdown data from 2016 to 2020 and forecast to 2021-2029.

About Us: Market Research Intellect

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations in addition to the objective of delivering customized and in-depth research studies.

We speak to looking logical research solutions, custom consulting, and in-severity data analysis lid a range of industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverages. Etc Our research studies assist our clients to make higher data-driven decisions, admit push forecasts, capitalize coarsely with opportunities and optimize efficiency by bustling as their belt in crime to adopt accurate and indispensable mention without compromise.

Having serviced on the pinnacle of 5000+ clients, we have provided expertly-behaved assert research facilities to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony, and Hitachi.

Contact us:

Mr. Edwyne Fernandes

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Website: https://www.marketresearchintellect.com/

Originally posted here:
Breast Cancer Predictive Genetic Testing Market To Observe Exponential Growth By 2021-2028 | Roche, Thermo Fisher Scientific, PerkinElmer, Quest...

A Wadsworth woman was reunited with a son she put up for adoption33 years ago.

Beacon Journal partner News 5 Cleveland reports that the woman found her son through 23andMe, a DNA genetic testing service.

Melanie Pressley told News 5 that she was 18 when she was pregnant with her first son. She knew she couldn't take care of him financially, and she wanted him to have a mom and dad, so she put him up for adoption through an agency in Akron.

She gave birth to him in 1988, which was the last time she saw her son.

News 5 reports that her son, Greg Vossler, was adopted by a family in Stow. At age 7, he and his family moved to Winchester, Virginia.

Pressley had gone on to become happily married and had more children, but she always wondered about her son, she told News 5. Eventually, Vossler also wanted to know more about his biological parents.

He took a 23andMe test in 2019. She took one in May 2021, and the tests matched them together.

Instantly sent a message, and my first message wasI believe we're related, said Pressley. The next message wasI believe I am your birth mother. And from there it just blew up.

One of the very first questions I asked him, which was big for me, was, Are you happy? And he came back that he was oh, my gosh that he's married, he has two boys. I mean, it was just like spilling everything, Pressley said.

In June, the two met in Wadsworth and saw each other for the first time in 33 years.

Vossler told News 5 thathe and Pressley talked for four hours straight that first day. He also met 17 members of his new extended family.

Everyone's emotional, everyone's shaking hands or hugging. And, you know, Hey, I'm your half-brother, your half-sister. And her oldest sister, who was instrumental in allowing Melanie to have that first picture, came up and grabbed my face. The first time in 33 years that she's seen me, Vossler said.

It's an amazing feeling. And it just goes to show that there's always room for families to grow and always room for more love within each other, Vossler said.

The two are continuing to nurture their new relationship, News 5 said, with Pressley planning to visit Vossler in Virginia soon.

Read more about the story from News 5 Cleveland here.

Read the original:
Wadsworth woman reunited with son she put up for adoption after 33 years - Akron Beacon Journal

WADSWORTH, Ohio For years, a Medina County woman has wondered about the son she gave up for adoption more than three decades ago.

What does he look like? What does he do for a living? Was he happy?

Well, thanks to the popular DNA genetic testing service 23andMe, she now has those answers and more.

Melanie Pressley was just 18 when she got pregnant with her first child a boy. Her boyfriend at the time wasnt supportive and wanted her to get an abortion. Pressley refused and continued on with the pregnancy.

But eventually, she knew she couldnt keep him.

I just knew, financially, I wouldn't be able to do it. And the other thingI wanted him to have a mother and father, so I decided at that point it was best to put him up for adoption, said Pressley.

With the support of her family, she went through the adoption process with an agency based in Akron.

On June 17, 1988, she gave birth to her son at the then-Timken Mercy Hospital in Canton. She didnt name him because she wanted his adoptive parents to have that honor.

She said that day, she wasnt allowed to hold him, but the next day, her sister asked a nurse if they could hold the baby.

She said, I will take you into a private room so that she can hold him, and she said, Take all the time you need. And at that point, when I was holding him, my sister took a picture and that was the only picture that I had of him for thirty three years. That was the only picture that I had of him, said Pressley.

Pressley has had three more kids since then and is happily married, but she said every day, and especially every time June 17 rolled around, she thought about the son she gave up for adoption.

There was still always a little bit of that sadness in me on that day. And that's basically the easiest way to describe it, said Pressley.

In Winchester, Virginia, 307 miles away from her Wadsworth home, it turns out Pressleys son was thinking of her too.

He was adopted by the Vossler family and named Greg. They lived in Stow for about seven years after he was adopted, and then moved to Winchester.

Maybe nine or 10 or somewhere around that age range, they shared with me the story that I was adopted and that the woman who gave me up for adoption thought I could have a better life elsewhere, said Vossler, who still lives in Winchester.

Vossler said his curiosity wasnt immediate.

Some years later, he found descriptions of his birth parents that were provided from accounts from the hospital, but there werent any names, birth dates, or ages.

Never was really curious. I'd always joke saying, you know, I don't see a celebrity that looks like me, or, No one who's a king or queen in some faraway land resembles me. And I always said that was just my joke. You know, whenever somebody asked, it was just my way of having that quick response in my back pocket, I'd never really given it some serious thought, said Vossler.

But he said it was always in the back of his mind through college, getting married, and raising two sons.

The reason I named my first son Gregory was because he was my first blood relative that I knew. So I wanted to have that bond, said Vossler.

Then, in 2019, he decided he wanted to know more.

My wife and I were sitting and talking one night, and I'm like, I don't know any of my medical history, genetics, you know, where I'm from. And there was a 23andMe promotion or something going on. And so I took the test, said Vossler.

That same year, Melanies mom died, which pushed her to do what shes always wanted to.

It was always my wish that I wanted him to meet my mother, but she passed away. And the night that she passed away, we were all around the table, my nieces, nephews, my sisters and everybody. And we were going around just kind of saying things and it got to me and I had just started crying and I said, I need to find my son, said Pressley.

But that moment didnt come until May 2021, when one of Melanie's daughters bought her a 23andMe test as a birthday gift.

The results came back in just days and with them a match to a potential son named Greg Vossler.

Instantly sent a message, and my first message was, I believe we're related, said Pressley. The next message was, I believe I am your birth mother. And from there it just blew up.

One of the very first questions I asked him, which was big for me, was, Are you happy? And he came back that he wasoh my goshthat he's married, he has two boys. I mean, it was just like spilling everything, said Pressley.

Messages on 23andMe turned into emails and finally texts.

Vossler said they vetted each other thoroughly to make sure the connection was real.

We were very investigative with each other, you know, the hospital where I was born changed the name. So I said, Well, do you remember the hospital where I was born? And she said the name that it was back in 1988. And I was like, OK, alright we got there, and there were a few additional things that I had asked and she answered, she passed the test, said Vossler.

You're just sitting there and it's not something that you can ever prepare for mentally, and the way I would constantly describe it was just a surreal moment, said Vossler.

But when Vossley asked if he could call Pressley, she told him she didnt want to hear his voice until she could see him in person.

So in June, Vossler, his wife Chelsea, and their sons drove to Wadsworth for a weekend.

Both Vossler and Pressley were worried that the connection wouldnt happen, and that it was somehow all a farce, but they were happily mistaken.

Vosslers wife took a photo of when the two saw each other for the first time.

I am so thankful for her for doing that because It was the very first time and it was awesome, said Pressley.

Vossler said he and Pressley talked for four hours straight that first day. He also met 17 members of his new extended family, including two of his siblings, his aunts, and grandfather.

Everyone's emotional, everyone's shaking hands or hugging. And, you know, Hey, I'm your half brother, your half sister. And her oldest sister, who was instrumental in allowing Melanie to have that first picture, came up and grabbed my face. The first time in 33 years that she's seen me, said Vossler.

It's an amazing feeling. And it just goes to show that there's always room for families to grow and always room for more love within each other, said Vossler.

Pressley and Vossler are continuing to nurture their newfound bond. Pressley and her husband, Tim, plan to travel to Virginia this weekend to meet the Vossler family.

Vossler and his family have also been invited to his half-sisters wedding this fall and plans to attend.

I am just excited with the ball moving and I am just going to soak up every moment and just enjoy it. Enjoy the little ones also with every opportunity that we get to see them, said Pressley.

Now, the picture that Pressleys sister took of them 33 years ago in the hospital isnt the only one this mother and son have together.

Life has a funny way of giving you what you need, not what you want. And I guess life just realized that we needed this connection and our families needed each other, said Vossler.

Jade Jarvis is a reporter at News 5 Cleveland. Follow her on Facebook, Twitter, and Instagram.

Download the News 5 Cleveland app now for more stories from us, plus alerts on major news, the latest weather forecast, traffic information and much more. Download now on your Apple device here, and your Android device here.

You can also catch News 5 Cleveland on Roku, Apple TV, Amazon Fire TV, YouTube TV, DIRECTV NOW, Hulu Live and more. We're also on Amazon Alexa devices. Learn more about our streaming options here.

More:
Wadsworth woman finds son she put up for adoption 33 years ago through 23andMe - News 5 Cleveland

BALTIMORE & HOUSTON--(BUSINESS WIRE)--Tesis Labs, a leader in targeted genetic sequencing, and Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, today announced a new collaboration to maximize the power of genetic sequencing and bioinformatics. Through this collaboration, the companies intend to combine resources and expertise to create new genomics solutions that could combat cancer and improve outcomes for patients, and advance market access initiatives to accelerate adoption in the market.

The National Institutes of Health estimates that by 2040, there will be 29.5 million new cancer cases and nearly 16.4 million deaths worldwide per year. This new strategic collaboration brings together highly specialized clinical laboratory and biotechnology teams, enabling their expertise, creativity, and passion for delivering the latest genetic and bioinformatic insights to advance cancer predisposition, profiling, and treatment.

We are excited to partner with PGDx and leverage our aligned vision and collective expertise to enable new and creative clinical opportunities, stated Ron King, Tesis Labs CEO. Genetic sequencing and genetic biomarkers are revealing new opportunities for medicine. Our clinical expertise and approaches to unlocking the power of genetic sequencing are bringing new insights to cancer research, profiling and treatment.

We are thrilled to partner with Tesis Labs, a company that shares our passion for expanding the reach of genetic sequencing through decentralized testing, said Megan Bailey, Chief Executive Officer of PGDx. We look forward to working with Tesis Labs to further progress advancements in genomic insights and patient-centered oncology care.

Tesis uses a genetically integrated medical platform for targeted genetic sequencing and comprehensive genetic data collection to support many medical specialties. The companys existing labs are in Denver, Lafayette, Colo., and Houston.

PGDx currently offers three pan-cancer NGS kitted solutions elio tissue complete, an FDA cleared kit, elio plasma complete, a comprehensive liquid biopsy solution, and elio plasma resolve, which has received FDA breakthrough device designation that provide researchers and clinicians with the ability to identify biomarkers and profile tumors through advanced genomic sequencing within their own hospital systems and laboratories.

About Tesis Labs

Tesis Labs' genetically integrated medical platform has revolutionized targeted genetic sequencing. Our mission is to change medicine by providing physicians, hospitals, and researchers with the tools to help patients treat and overcome major chronic conditions such as heart disease, lung disease, cancer, and diabetes through advanced genetic testing. Tesis offers healthcare providers and physicians access to our unique genetic testing and precision medicine, enabling them to create personalized care plans for treating chronic diseases individually and across generations. We also enable medical device companies and pharmaceuticals to bring new products to market and create a robust repository of genetic data and research. Visit http://www.tesislabs.com to learn more.

About Personal Genome Diagnostics

Personal Genome Diagnostics (PGDx) empowers the fight against cancer by unlocking actionable information from the genome. We are committed to improving clinical insight, speed of results, and healthcare economics by delivering a portfolio of regulated tissue-based and liquid biopsy genomic products for health systems worldwide. PGDx was established by researchers from Johns Hopkins University who are pioneers in cancer genome sequencing and liquid biopsy technologies. PGDxs elio Platform has enabled the development of standardized tissue-based and liquid biopsy next-generation sequencing (NGS) kits for laboratories worldwide, featuring automated bioinformatics that ensures consistent results and quality of testing. By automating the data analysis process, PGDx is enabling the scalability of precision medicine with a fast, reliable, and accurate diagnostics platform. For additional information, visit http://www.pgdx.com.

Read more here:
Tesis Labs and Personal Genome Diagnostics Announce Collaboration to Advance Cancer Profiling and Treatment - Business Wire

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

DELRAY BEACH, Fla.--(BUSINESS WIRE)--Genetics Institute of America announced today that it has undergone an Accreditation Inspection by the College of American Pathologists (CAP) and passed with no deficiencies.

A team from the College of American Pathologists performed a general laboratory and molecular pathology accreditation inspection on Tuesday, August 10th. The purpose of this inspection is to help laboratories maintain accuracy of test results and ensure accurate patient diagnosis. CAP inspections are a part of the accreditation and inspection cycle.

This successful CAP inspection validates our quality assurance and management practices and ensures that we are providing the best in physician and patient-centered genetic testing services, said Dr. Ana Perez-Miranda, Laboratory Manager for Genetics Institute of America.

Our mission at Genetics Institute of America is to save lives, change lives and give back, said Holly Magliochetti, CEO and Founder. Our Team knows that the work we do has a multi-generational impact, and this CAP accreditation is a very important step to continue to uphold the most stringent clinical laboratory testing standards in molecular and Next Generation Sequencing.

The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal-to or more-stringent-than the governments own inspection program. According to the CAP, they accredit the entire spectrum of laboratory test disciplines using the most scientifically rigorous customized checklist requirements. These checklists are developed from rigorous accreditation standards that are more stringent than or equal to the requirements of the Clinical Laboratory Improvement Program (CLIA). They are designed to cover regulatory compliance requirements and assist laboratories in achieving the highest standards of excellence for positively impacting patient care.

About the College of American Pathologists (CAP)

As the worlds largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. Built on more than a half-century of experience, the CAPs Laboratory Accreditation Program has been the champion of laboratory excellence. We are recognized as the global leader in improving the quality of services using established performance standards. For more information, READ THE CAP ANNUAL REPORT at http://www.cap.org.

About Genetics Institute of America

Genetics Institute of America is a national laboratory dedicated to heightening the awareness of early intervention and genetic screening to promote longevity and quality of life outcomes by focusing on DNA, RNA and Proteins. Our modern CLIA certified, CAP accredited laboratory facility in Delray Beach, FL specializes in high complexity molecular testing and contains the most current technology, allowing us to provide leadership in both research and clinical laboratory testing. For more information, please visit http://GenlabUS.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210812005857/en/

Holly Magliochettimedia@GenLabUS.com

Source: Genetics Institute of America

Read the rest here:
Genetics Institute of America Receives Accreditation from the College of American Pathologists - StreetInsider.com

Zolgensma is a novel drug that was approved by the US Food and Drug Administration (FDA) in May 2019 as an one-time gene therapy for children with spinal muscular atrophy (SMA), said the National University Hospital in an e-mail reply to The New Paper yesterday.

Valued at US$2.125 million (S$2.9 million)for each patient, it is said to be the most expensive drug in the world.

SMA is diagnosed through genetic testing. Besides treatment, patients are usually supported symptomatically, with physiotherapy to manage muscle weakness and prevent complications like contractures.

They are also supported by medical means such as appropriate seating and mobility devices, respiratory support, as well as regular therapy.

"Aside from Zolgensma, other options of treatment for SMA include the use of other drugs and supportive treatment.

"These alternative options for SMA include Spinraza, a recurring therapy given intrathecally every four months, and Risdiplam, an oral medication administered daily," said NUH.

Zolgensma is administered intravenously as a single dose over 60 minutes.

While it has a hefty price tag, the other treatments are also expensive. The Spinraza costs more than $1 million for the five or six injections required in the first year of treatment, and an annual amount of a little over $500,000 for three injections each year subsequently. The Risdiplam oral treatment costs around $460,000 a year.

Zolgensma manufacturer, US-based biopharmaceutical company Novartis Gene Therapies, has stated that the drug is designed to target the genetic root cause of SMA by replacing the function of the missing or non-working survival of motor neuron 1 (SMN1) gene with a new, working copy of a human SMN gene.

Child neurologist Wendy Liew of Dr Wendy Liew Paediatric and Child Neurology Centre said while none of the three FDA-approved treatments for SMA are available in Singapore, they can be imported under the Health Sciences Authority's (HSA) Special Access Route.

On HSA's website, it is stated that the named-patient application allows a licensed hospital or clinic to import and supply an unregistered therapeutic product that presents a life-saving treatment option to the patient whose condition would be clinically compromised without the requested therapy, and that there is no effective alternative therapy registered in Singapore.

TNP understands the approval of such applications usually takes 14 working days and needs to be done before buying the treatment for import.

When asked if any treatment is superior to the others, Dr Liew said: "There are many considerations (when selecting a treatment), such as the age of the patient, the route of administration, the expected benefit, the anticipated adverse effects and the cost of each treatment.

"At the moment, all three treatments have been proven to work, so it is hard to say that one is definitely better than the others."

See the original post:
Hefty price tag for treatment of spinal muscular atrophy - The New Paper

China in vitro diagnostics(IVD) market is anticipated to grow over US$ 11 Billion by 2025 with an impressive double-digit growth rate in the forecast period 2018 2025.

The market is driven by number of factors such as rising incidences of chronic lifestyle diseases, public health awareness, demand of tests in rural areas stimulated by the healthcare reform plan, increasing demand from the middle class for highend products and an increase in the number of private hospitals and independent testing laboratories.

Get FREE Sample copy of this Report with Graphs and Charts [emailprotected]https://www.trendsmarketresearch.com/report/sample/3888

China In Vitro Diagnostics (IVD) Market Analysis 2012 2017 and Forecast 2018 2025: Clinical Chemistry,Immunoassay,Molecular Testing,SMBG,Point of Care Testing (POCT), Hematology, Coagulation, Microbiology, Genetic Testing, Infectious Diagnostics, Histology and Cytology presents an in-depth assessment of the in vitro diagnostics(IVD) market dynamics, opportunities, future roadmap, competitive landscape and discusses major trends. The report offers the most up-to-date industry data on the actual market situation and future outlook for in vitro diagnostics(IVD) in China. The research includes historic data from 2012 to 2017 and forecasts until 2025.

The report contains a granular analysis of the China in vitro diagnostics market segmentation by 11 applications and illustrative forecast to 2025.A comprehensive analysis has been done on market share of China in vitro diagnostics by application, end-user and company share by revenue.

The report also includes assessment of in vitro diagnostics regulation in China.Key trends in terms of partnerships and recent developments are analyzed with details. The report also explores detailed description of growth drivers,restraints, trends and opportunities of the China in vitro diagnostics market.

Market Segmentation by Application and Analysis (2012 2025)

Clinical Chemistry Immunoassay Molecular Testing SelfMonitoring of Blood Glucose (SMBG) Point of Care Testing (POCT) Hematology Coagulation Microbiology Genetic Testing Infectious Diagnostics Histology and Cytology

Checkout Inquiries to Purchase or Customize the Market @https://www.trendsmarketresearch.com/checkout/3888/Single

The Major Companies Dominating this Market for its Products, Services and Continuous Product Developments are:

Roche Diagnostics Abbott Laboratories Siemens Healthineers Sysmex Corporation Mindray Medical International Limited Beckman Coulter Inc Shanghai Fosun Pharmaceutical Group Thermo Fisher Scientific Inc Hologic Inc Qiagen Cepheid Bio-Rad Laboratories Inc Da An Gene Co. Ltd Shanghai Kehua BioEngineering Co. Ltd.

The Latest Industry Data Included in this Report:

China In Vitro Diagnostics Market Revenue & Forecast (2012 2025) China In Vitro Diagnostics Market Dynamics China In Vitro Diagnostics Market Segmentation by Application (2012 2025) China In Vitro Diagnostics Market Revenue Share by Application (2012 2025) China In Vitro Diagnostics Market, Company Share by Revenue, 2017 China In Vitro Diagnostics Market Share by End-User (Hospitals, Homecare, Research Institutes, Independent laboratories),2017 Assessmentof In Vitro Diagnostics Regulation in China Major Partnership Deals in China In Vitro Diagnostics Market Recent Developments in China In Vitro Diagnostics Market Overview of Key Companies in China In Vitro Diagnostics Market

Get up to 50% discount on this report [emailprotected]https://www.trendsmarketresearch.com/report/discount/3888

Read the original:
China In Vitro Diagnostics (IVD) Market growth graph to witness upward trajectory during 2021-2026 - The Market Writeuo - The Market Writeuo

New Jersey, United States,-Verified Market Research recently released a new report titled Cannabis Testing MarketSize Report, Growth and Forecast 2021-2028, Breakdown Data by Company, Key Regions, Types and Applications. The report has been compiled using primary and secondary research methodology that will provide a precise and precise understanding of the Cannabis Testing market. Analysts used a top-down and bottom-up approach to assess the segments and properly assess their impact on the Cannabis Testing market. The report offers a market overview which briefly describes the market situation and major segments. It also mentions the best players represented in the Cannabis Testing market.

The 2021 report offers an in-depth analysis of each sector of this Cannabis Testing industry. Fill in historical Cannabis Testing data according to customer requirements. It offers Cannabis Testing market research globally and locally. The detailed segment and manufacturer information of Cannabis Testing helps guide future benefits and make important decisions for the growth of Cannabis Testing.

Get | Download Sample Copy with TOC, Graphs & List of Figures @https://www.verifiedmarketresearch.com/download-sample/?rid=22449

The report covers extensive analysis of the key market players in the market, along with their business overview, expansion plans, and strategies. The key players studied in the report include:

Shimadzu Corporation, Millipore Sigma, Restek Corporation, SC Laboratories Agilent Technologies Inc., Waters Corporation, PerkinElmer Inc., AB SCIEX LLC, CannaSafe Analytics and Steep Hill Labs.

Cannabis Testing Market Segmentation

Cannabis Testing Market, By Product And Software

Products Software (Cannabis LIMS)

Cannabis Testing Market, By Service

Potency Testing Pesticide Screening Heavy Metal Testing Genetic Testing Others

Cannabis Testing Market, By End-User

Laboratories Drug Manufacturers

In the next chapters, the research report reveals the development of the Cannabis Testing market segments. Analysts have segmented the market on the basis of product, application, end-users, and geography. Each segment of the Cannabis Testing market has been studied with in-depth insight. Analysts have evaluated the changing nature of the market segments, growing investments in manufacturing activities, and product innovation that are likely to impact them. In terms of geography, the report studies the changing political environment, social upliftment, and other government initiatives that are expected to contribute to the regional markets.

Get Discount On The Purchase Of This Report @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=22449

Cannabis Testing Market Report Scope

Geographic Segment Covered in the Report:

North America (USA and Canada) Europe (UK, Germany, France and the rest of Europe) Asia Pacific (China, Japan, India, and the rest of the Asia Pacific region) Latin America (Brazil, Mexico, and the rest of Latin America) Middle East and Africa (GCC and rest of the Middle East and Africa)

Key questions answered in the report:

For More Information or Query or Customization Before Buying, Visit @ https://www.verifiedmarketresearch.com/product/cannabis-testing-market/

Visualize Cannabis Testing Market using Verified Market Intelligence:-

Verified Market Intelligence is our BI-enabled platform for narrative storytelling of this market. VMI offers in-depth forecasted trends and accurate Insights on over 20,000+ emerging & niche markets, helping you make critical revenue-impacting decisions for a brilliant future.

VMI provides a holistic overview and global competitive landscape with respect to Region, Country, and Segment, and Key players of your market. Present your Market Report & findings with an inbuilt presentation feature saving over 70% of your time and resources for Investor, Sales & Marketing, R&D, and Product Development pitches. VMI enables data delivery In Excel and Interactive PDF formats with over 15+ Key Market Indicators for your market.

Visualize Cannabis Testing Market using VMI @ https://www.verifiedmarketresearch.com/vmintelligence/

About Us: Verified Market Research

Verified Market Research is a leading Global Research and Consulting firm that has been providing advanced analytical research solutions, custom consulting and in-depth data analysis for 10+ years to individuals and companies alike that are looking for accurate, reliable and up to date research data and technical consulting. We offer insights into strategic and growth analyses, Data necessary to achieve corporate goals and help make critical revenue decisions.

Our research studies help our clients make superior data-driven decisions, understand market forecast, capitalize on future opportunities and optimize efficiency by working as their partner to deliver accurate and valuable information. The industries we cover span over a large spectrum including Technology, Chemicals, Manufacturing, Energy, Food and Beverages, Automotive, Robotics, Packaging, Construction, Mining & Gas. Etc.

We, at Verified Market Research, assist in understanding holistic market indicating factors and most current and future market trends. Our analysts, with their high expertise in data gathering and governance, utilize industry techniques to collate and examine data at all stages. They are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research.

Having serviced over 5000+ clients, we have provided reliable market research services to more than 100 Global Fortune 500 companies such as Amazon, Dell, IBM, Shell, Exxon Mobil, General Electric, Siemens, Microsoft, Sony and Hitachi. We have co-consulted with some of the worlds leading consulting firms like McKinsey & Company, Boston Consulting Group, Bain and Company for custom research and consulting projects for businesses worldwide.

Contact us:

Mr. Edwyne Fernandes

Verified Market Research

US: +1 (650)-781-4080UK: +44 (753)-715-0008APAC: +61 (488)-85-9400US Toll-Free: +1 (800)-782-1768

Email: [emailprotected]

Website:- https://www.verifiedmarketresearch.com/

View original post here:
Cannabis Testing Market Size, Analysis, Competitive Strategies and Forecasts to 2028 - The Market Writeuo - The Market Writeuo

Abstract

Male breast cancer is a rather uncommon and understudied disease. It accounts for less than 1% of all breast cancers, but in recent decades its frequency has been on the rise. Clinical trials of breast cancer have traditionally excluded men. Due to the lack of large-scale prospective studies, most published data come from single-institution, small-cohort studies, and treatment recommendations are based on the extrapolation of data from clinical trials enrolling only women. Although to some extent etiology, diagnosis, and treatment characteristics can be similar, male breast cancer exhibits some distinct features. Men tend to be diagnosed with breast cancer at an older age and at a more advanced stage. A better understanding of the biologic features, clinically relevant differences, effective treatments, and outcomes of male breast cancer is crucial to appropriately manage these patients. We present a male breast cancer case with a germline BRCA2 mutation and discuss the epidemiologic, pathologic, and clinical characteristics along with treatment and follow-up recommendations in view of our recent understanding of this disease.

Male breast cancer is a rare disease accounting for less than 1% of all breast cancers, and less than 1% of all cancers in men. Worldwide estimated incidence of male breast cancer has been reported to be 1 per 100,000 men per year, with a mean age at diagnosis of 60 to 70 years.1,2 The average age at diagnosis is approximately 5 years older than it is for women (67 years vs 62 years, respectively).3 Based on data from the Surveillance, Epidemiology, and End Results (SEER) program, the age-adjusted incidence rate has increased from 0.85 cases per 100,000 in 1975 to 1.43 cases per 100,000 in 2011. Black men appear to be at greater risk than non-Hispanic White men.4,5

Male breast cancer seems to be an estrogen-driven disease; it has been likened to late-onset, postmenopausal, estrogen receptor/progesterone receptorpositive (ER+/PR+) female breast cancer.6 Male breast cancer tends to occur at a later age and to present at a more advanced stage, with more hormone receptor positivity.7 However, there are differences, resulting in an ongoing debate regarding the level of similarity.

Male breast cancer may be a unique tumor type with biological and clinicopathological features distinct from female breast cancer. However, similar to female breast cancer, family history has been shown to be an important risk factor.8,9 The risk of breast cancer doubles for men who have a first-degree relative with the disease.10 Population-based studies indicate that mutations in the 2 major high-penetrance breast cancer genes, BRCA1 and BRCA2, account for approximately 10% of male breast cancers11; 0% to 4% of men with breast cancer have BRCA1 mutations and 4% to 16% have BRCA2 mutations.8,9,12,13 The lifetime risk of developing male breast cancer has been estimated to be in the range of 1% to 5% for BRCA1 and 5% to 10 % for BRCA2 mutation carriers, compared with a risk of 0.1% in the general population.14-17

Genes other than BRCA1/2 may also be involved. A truncating mutation (CHEK2*1100delC) has been shown to increase the risk of male breast cancer by a factor of 10, compared with the risk among men who do not have the mutation.13,18 Also reported have been mutations in other genes, including the PTEN tumor suppressor gene and the androgen receptor gene, as well as TP53 mutations (Li-Fraumeni syndrome), PALB2 mutations, and mismatch repair mutations associated with hereditary nonpolyposis colorectal cancer (Lynch syndrome).13,19-21 Other risk factors for male breast cancer are hormonal imbalances (caused by liver disease, Klinefelter syndrome, or obesity) and environmental factors (eg, chronic exposure to heat or radiation).22-26

A White man, aged 64 years, presented with complaints of a palpable lump on the upper outer quadrant of his left breast along with some pain for the past several months. On physical exam, he was noted to have a 2.5-cm left breast mass along with retraction of the retroareolar and nipple region without discharge (Figure 1). A left breast mammogram showed scattered areas of fibroglandular density throughout the breast. Ultrasound (US) confirmed a 1.9 cm 1.7 cm irregular hypoechoic mass with no identifiable axillary nodes. US-guided biopsy reported an invasive ductal carcinoma grade 3, ER+ (85%), PR negative (<1%), HER2 negative, and Ki-67 (30%). MRI of the bilateral breasts confirmed a retroareolar mass on the left consistent with known malignancy, with no chest wall or axillary involvement, and normal appearance of the right breast (Figure 2).

The patient was treated with left mastectomy and axillary sentinel lymph node (LN) sampling. Pathology revealed a 2.1-cm invasive ductal carcinoma, grade 3, with no ductal carcinoma in situ (DCIS) (Figure 3). One of the 3 sentinel nodes showed isolated tumor cells. Pathologic stage was pT2, pN0(i+). Tumor Oncotype-Dx Breast Recurrence Score (BRS) was 42. Pretest cancer genetic counseling followed by germline targeted multigene mutation analysis revealed a pathogenic mutation, c.1147delA in the BRCA2 gene, consistent with hereditary breast and ovarian cancer (HBOC) syndrome. Family pedigree is shown in Figure 4.

The most common clinical presentation in men with breast cancer is a painless, retroareolar mass. Nipple retraction, bleeding from the nipple, skin ulceration, and palpable axillary adenopathy are among other reported signs and symptoms.27 To differentiate from gynecomastia, a highly prevalent condition, breast imaging should be considered. The American College of Radiology recommends initial US for men aged younger than 25 years with an indeterminate palpable mass. For men 25 years or older or those with questionable findings on physical examination, mammography is recommended as the initial diagnostic test followed by US if the mammographic findings are inconclusive or suggestive of cancer.28 On mammograms, male breast cancers appear as eccentric, retroareolar masses with irregular, spiculated edges.29,30 Due to low public awareness and the lack of screening mammograms for men, male breast cancers are more frequently diagnosed as larger tumors with regional nodal metastases.31 Staging for breast cancer in men is the same as for women with no gender-specific recommendations.

Men with abnormal imaging findings suggestive of malignancy should undergo core biopsy to confirm the diagnosis. Approximately 10% of men with breast cancer present with DCIS compared with 20% to 25% of women. Lobular carcinoma in situ in men is very rare due to anatomical absence of terminal lobules in the male breast. Most male breast cancer cases are invasive ductal carcinomas, but rarely papillary cancers (in 2% to 3% of cases) and mucinous cancers (in 1% to 2% of cases) can be seen.3,32,33 Invasive lobular carcinoma is much less prevalent among men, accounting for only 1% to 2% of cases.3,34 In the largest series of male patients with breast cancer analysis, tumor samples from 1483 men showed 99% ER+, 97% androgen receptor positive, 87% PR+, and 9% HER2+. Less than 1% of male breast cancer specimens were triple negative.34

In a genomic profiling study of 59 male patients with breast cancer, 29% of samples were classified as luminal Alike and 71% as luminal Blike, with a heterogeneous repertoire of somatic genetic alterations. PIK3CA and TP53 mutations, and losses of 16q, which are typically seen in ER+/HER2-negative female breast cancers, were less frequent in male breast cancer samples. Mutations affecting DNA repairrelated genes were more frequent.35 Using unsupervised clustering approach, a gene-expression analysis study identified 2 unique and stable subgroups of male breast cancer with differences in tumor biological features and outcome: luminal M1 tumors with low expression of ER signaling genes, aggressive clinical behavior, and worse prognosis; and luminal M2 tumors with activated ER signaling genes, upregulated immune response genes, and favorable clinical behavior. Both subgroups differed from the established 4 intrinsic subgroups of female breast cancer.36

Evidence from observational studies shows that breast-conserving therapy in men is associated with similar survival rates as mastectomy.37-40 Interestingly, however, men with breast cancer, even in early-stage disease, are being treated with mastectomy and either with axillary LN dissection or sentinel node biopsy despite the absence of any medical contraindication for breast conservation. Based on a SEER registry data analysis, only 18% of men with T1N0 tumors underwent breast-conserving surgery.38 Sentinel node biopsy, the standard approach for women with a clinically negative axilla, has been shown to be feasible and effective in men with breast cancer.41,42

Due to the rarity of male breast cancer and lack of randomized trials, the role of radiotherapy after mastectomy in node-positive male breast cancer has not been well studied. Hypofractionated radiotherapy regimens have not been tested in male breast cancer, as men were excluded from the UK START trials as well as the Canadian trial(NCT00156052.)43-44As adjuvant radiotherapy has been shown to decrease the rate of relapse, adjuvant radiotherapy should be offered to men who have undergone breast-conserving surgery, based on the same guidelines developed for women with breast cancer.2 Indeed, population-based observational studies suggest a benefit in this setting.45-47

In real-world practice, however, radiotherapy seems to be underutilized in men with breast cancer. Also, patient compliance rates with adjuvant radiation therapy seem to be generally low. Based on the SEER data, only 42% of men with stage I breast cancer received radiotherapy after breast-conserving surgery.38,48 Recently published National Cancer Data Base study data are somewhat encouraging and show that adjuvant radiotherapy was given to 70% of patients undergoing breast-conserving surgery in stage I to III male breast cancer.49 Worldwide data involving 1483 male patients with breast cancer treated between 1990 and 2010, examined in a retrospective study in collaboration with the European Organization for Research and Treatment of Cancer, the Translational Breast Cancer Research Consortium, the North American Breast Cancer Group, and the Breast International Group period, showed that about one-half of men who were treated with breast-conserving surgery did not receive radiotherapy.34

Due to exclusion of male patients with breast cancer from clinical trials involving female breast cancer, there are no randomized studies of adjuvant or neoadjuvant chemotherapy or of HER2-targeted therapy in this population. There has been 1 reported prospective National Cancer Institute study evaluating adjuvant chemotherapy in 31 men who had stage II breast cancer with LN involvement. Patients were treated with mastectomy and 12 cycles of cyclophosphamide, methotrexate, and fluorouracil between 1974 and 1988. This cohort was followed for more than 20 years; survival was 80% at 5 years, 65% at 10 years, and 42% at 20 years, comparing favorably with historical rates.50 In a more recent study of 32 men with breast cancer treated with systemic adjuvant/neoadjuvant chemotherapy, the 5-year and 10-year overall survival rates were 86% and 75%, respectively, for men with LN-negative disease, and 70% and 43%, respectively, for men with LN+ disease. For men with LN+ disease, adjuvant chemotherapy was associated with a lower risk of death (HR, 0.78).51 Additional observational cohort studies in men have suggested improved survival with the use of adjuvant chemotherapy.52-55

Since the majority of male breast cancers are HR+, endocrine therapy plays an important role in both in the adjuvant and metastatic settings. Observational studies of adjuvant treatment with tamoxifen suggest a survival benefit. Male patients with breast cancer were shown to benefit more from endocrine therapy with tamoxifen than from aromatase inhibitors (AIs) in a cohort of 257 patients.56,57 Population-based series have shown inferior survival rates when men were treated with adjuvant AIs as compared with tamoxifen. The lack of complete estradiol suppression due to feedback loops in the hypothalamus and pituitary glands has been shown to be the reason for the lower efficacy of AIs in men.58,59 For men who are not good candidates for tamoxifen, a GnRH analogue with or without an AI can be used to overcome this.60

Gene expression profiling assays have been widely used to quantify the risk of recurrence as well as to guide systemic therapy in early-stage breast cancer in women. The 21-gene BRS and 70-gene MammaPrint assay tests provide individualized estimates of distant recurrence risk and help predict benefit from adjuvant chemotherapy in women with ER+ breast cancer.61 Data on the utility of these assays in male patients with breast cancer are limited. Crozier et al reported that while similar MammaPrint index distributions between male and female breast cancer tumors existed, there were distinct biological pathways between male and female breast cancernotably, upregulation of estrogen response and MTORC1 signaling in male compared with female breast cancer specimens.62 Similarly, Oncotype DX results have shown comparable mean BRS in men and women, but mean quantitative gene expression for genes related to ER, proliferation, and invasion were higher in men compared with women.63-65

Germline mutations in BRCA1/2 are inherited in an autosomal dominant manner with the majority of individuals having inherited it from a parent (de novo rate 5%).66 The parent with the mutation may or may not have had a cancer diagnosis for several reasons, including penetrance of the mutation, gender and age of the parent, cancer risk reduction due to screening/prophylactic surgeries, or early death.67 It is appropriate to offer germline testing to both parents of an individual with a BRCA1/2 mutation to determine which side of the family is at risk; however, the parent with the family history of BRCA1/2-related cancers can be tested first. Being a carrier of a BRCA1/2 mutation also comes with reproductive risks. For example, in cases where both partners carry a BRCA2 mutation, there may be a high risk for the offspring to develop Fanconi anemia, a rare autosomal recessive condition.68 Additionally, a case has been found in which biallelic BRCA1 mutations caused a Fanconi anemialike disorder.69 The current estimates of the frequency of BRCA1 and BRCA2 gene mutations in the population is approximately 1 in 500 individuals.70

Male carriers of BRCA1/2 mutations are at increased risk for development of several types of cancers, including breast (BRCA1, 1.2% lifetime; BRCA2, 7% to 8% lifetime), prostate (BRCA1, exact risk unknown; BRCA2, 20% to 30% lifetime), pancreas (BRCA1, 2% to 3% lifetime; BRCA2, 3% to 5% lifetime), and melanoma (BRCA2, 3% to 5% lifetime).14,16,71-73 The National Comprehensive Cancer Network (v1.2021) recommends breast self-exam training and education starting at age 35 years, a clinical breast exam every 12 months starting at age 35 years, and consideration of annual mammogram screening in men with gynecomastia starting at age 50 years or 10 years before the earliest known male breast cancer in the family (whichever comes first).74

While tamoxifen can be used as a chemopreventive agent for female breast cancer, there are no data for men in this setting. Similarly, prophylactic mastectomy has not been offered due to lack of data to support this type of risk reduction. However, Jemal et al.75 reported an increase in contralateral mastectomy in men diagnosed with a unilateral breast cancer. The procedure was more common in younger, White, and privately insured patients. For male patients harboring BRCA2 mutations,prostate cancer surveillance with annual prostate-specific antigen and digital rectal examination beginning at age 40 years is recommended, and these should be considered for male BRCA1 carriers as well. Pancreatic cancer screening with contrast-enhanced MRI/ magnetic resonance cholangiopancreatography and/or endoscopic US is recommended for BRCA1/2 carriers at age 50 years (or 10 years younger than the earliest pancreatic cancer in the family, whichever comes first who have 1 or more first- or second-degree relatives with pancreatic cancer. No BRCA1/2-specific screening guidelines exist for melanoma, but general melanoma management, with annual full-body skin examination and minimizing ultraviolet exposure, is a sensible option.74

Here, we discuss a male patient with breast cancer presenting with a palpable mass; surgical treatment and staging led to a diagnosis of pT2, pN0(i+) invasive ductal carcinoma of the breast with a Oncotype Dx BRS of 42. Pretest cancer genetic counseling followed by germline targeted multigene mutation analysis revealed a pathogenic mutation, c.1147delA in the BRCA2 gene, consistent with HBOC syndrome.

Although breast cancer in men and in women is similar in some ways, thereremain gaps in our understanding of breast cancer in men. Examination of the biology of the disease would help identify the differences and determine whether identified differences have therapeutic implications. Further work that focuses on appropriate treatment of men with breast cancer is needed.

Following surgical treatment, the patient was treated with adjuvant chemotherapy (docetaxel/ cyclophosphamide) for 4 cycles; postmastectomy radiation; and adjuvant tamoxifen therapy to be given for 5 years. Currently he does not have any evidence of disease.

Financial Disclosure: The authors have no significant financial interest in or other relationship with the manufacturer of any product or provider of any service mentioned in this article.

References

View post:
A 64-Year-Old Man With Germline BRCA2-Mutated Breast Cancer: Known and Unknown Aspects of Male Breast Cancer - Cancer Network

One-third of the members of the editorial board of a leading American medical journal has resigned in protest against the publication of several research papers that could help the Chinese regime in its persecution of minorities. According to a report by The Intercept, after a slew of research papers that can help racial profiling of minorities in China were published by the journal named Molecular Genetics & Genomic Medicine, eight of the 25 editorial board members resigned in protest. The members protested after the management of the journal failed to take any action on the papers despite repeated complaints.

According to The Intercept, emails accessed by it shows that the editor-in-chief of the journal was slow in responding to several controversial papers related to Tibetans, Uyghurs and other ethnic groups in China. Molecular Genetics & Genomic Medicine is published by Wiley, a New Jersey based company, and the company also took a long time to respond to concerns about the papers published by the journal.

The papers under question were first flagged by Yves Moreau, a Professor of Engineering and a bioinformatician at the University of Leuven in Belgium, and according to The Intercept, he has been fighting a tireless campaign to get journals to retract troubling or unethical papers. He has been successful in getting an order of Kuwait govt overturned, which had called for compulsory DNA collection from all citizens.

He was studying the DNA profiling of the minorities done by the Chinese authorities. During such searches, he found 18 papers published by Molecular Genetics & Genomic Medicine, which dealt with various genetic topics related to the people in China. Some analysed the genetic differences between ethnic groups, including the genetic gaps between the majority Han community and minorities like Tibetans and Hui Muslims, and some had relied on samples that Moreau suspects were collected without proper consent.

Many of the papers were related to forensic genetics, a problematic subject in the entire scientific community. It refers to the collection of DNA for forensic databases, which is used by the police in criminal investigations. But although in theory it should be used only to find suspect criminals, it has the potential to conduct racial profiling, a highly problematic area. Moreover, scientists also worry about collection of DNA sample from ethnic minorities without their consent, which is happening in China.

The Chinese government is already DNA from its male citizens to build a massive a national forensic DNA database. Reportedly, the Communist government aims to collect and store genetic profiles of around 70 million people, around 10% of the countrys male population. Apart from that, Chinese police also forcibly collecting DNA samples from ordinary citizens, including migrant workers, dissidents, and minority Uyghur Muslims.

Although the Chinese govt says it is being done to fight crimes, researchers dont believe that, they say it is a part of the government efforts to deepen social control. Although most western countries collect DNA sample of convicts, the collection of such samples from ordinary citizens have been described as unprecedented. Human Rights Activists say the only purpose of this genetic profiling is the oppression of ethnic minorities by the Chinese govt.

This concern is being raised because of the kind of data collected by the Chinese govt. They are cataloguing markers known as short tandem repeats (STRs), which are repeating regions of DNA that are specific to the Y chromosome found in men. These STRs are extremely similar between men in the same male lineage, which means, when the authorities nab a dissident man, they can track all his male relatives using the database, even if they are not identified as relatives in official documents.

Since 2019, Molecular Genetics & Genomic Medicine has published several papers authored by Chinese authors on the topic of forensic genetics, which means they used samples collected by the police, many of which could be done without consent. Many of the papers listed institutions as co-authors which work closely with the police or receive funding from the police. One paper even lists the Public Security Bureau in Tibet as the co-author, which is the police agency in the region.

All these show that the research papers published by the American journal were effectively authored or sponsored by the Chinese govt.

After discovering the papers, Yves Moreau had written in March this year to Suzanne Hart, the journals editor-in-chief and deputy director at the medical genetics and genomic medicine training program with the U.S. National Institutes of Healths National Human Genome Research Institute. He noted that before 2019, the journal had published only two papers on forensic genetic studies from outside China, which shows that the Chinese govt has specifically identified the journal where the papers on forensic genetic studies of vulnerable Tibetan and Muslim minorities can be published.

However, although Suzanne Hart acknowledged the mail and promised to look into the matter, he received no update for months after that. As a result, he wrote to the entire Editorial Board in June, describing the concerns with the papers published by them. Many of the board members agreed with him for a probe in the matter, and many said that they were not even aware of the papers.

When the board members wrote to Hart, she said she will get back with further information on how the management intends to address this issue. But when no communication came from her for several weeks, the board members started to resign in protest. Ophir Klein, a board member and a pediatric medical geneticist at the University of California San Francisco said that he left the board as he was really concerned about the lack of communication.

However, not all editorial board members who question the paper have resigned, some have decided to stay on to push for scrutiny of the papers, including Joris Veltman, the dean of the Biosciences Institute at Newcastle University Medical School in UK. After he wrote to the management escalating the issue, they responded that Wiley would begin an investigation immediately.

After that, the company released a statement saying that the Integrity in Publishing Group of the company was overseeing the matter. However, they informed that they are only contacting with the authors and the institutional review boards associated with the published papers to clarify the consent procedures undertaken for collecting the DNA samples.

Although the consent was a major issue, it was not the only one. The company kept silence on the much larger issue of use of scientific instruments in racial profiling and discrimination by authoritarian governments. Moreau said the focus on consent is too narrow, and the larger question is whether the journal should be publishing research on vulnerable minorities, some of which directly involves the authorities persecuting them.

The board members are saying that if the papers are determined to be unethical, at least they should be retracted.

This is not the first time that Wileyhas been accused of allying with China. In September 2000, the editor of another journal published by the company had resigned over the issue of freedom of speech. Prof David Curtis, from University College Londons Genetics Institute, had resigned as the editor-in-chief of the Annals of Human Genetics, after he was prevented from publishing an article which said that academic journals should boycott papers from China protesting against Chinas human rights violations in Xinjiang.

Wiley, and Lancet which also refused to published the article, had said that publication of the article could pose difficulties for their offices in China. Yves Moreau was one of the co-authors of the article.

Read more:
One-third of editorial board members of American medical journal resign over papers that could help China persecute its minorities: Details - OpIndia

Ungulate keepers and scientists at the Smithsonian Conservation Biology Institute (SCBI) in Front Royal, Virginia, are celebrating the birth of two scimitar-horned oryx calves born via non-surgical artificial insemination. A male calf was born July 9 to 6-year-old female Esmerelda, and a female calf was born July 10 to 5-year-old female, Leanne. Both mothers and calves are doing well and bonding. As the calves grow, their vocalizations and play behavior with each other and interactions with the rest of the herd will increase.

Assisted reproduction for rare and endangered species is constantly evolving, said Budhan Pukazhenthi, reproductive physiologist at SCBI. Scimitar-horned oryx have similar estrous cycles to those of cattle, so we tried a protocol developed for the artificial insemination of livestock called CO-Synch. Narrowing the insemination window helped increase the chance of conception. These births are proof positive we can apply this protocol with increased success in scimitar-horned oryx population management in zoos and for animals being prepared for reintroduction to the wild.

Though once distributed across most of North Africa, scimitar-horned oryx are currently considered extinct in the wild due to a combination of widespread over-hunting, habitat loss and persistent drought.A reintroduction project led by the Environmental AgencyAbu Dhabi and including the Sahara Conservation Fund, the Zoological Society of London and SCBI is working collaboratively with the government of Chad and the international zoo community to return oryx to their native habitat. The first release, consisting of 23 individuals bred in human care, began in 2016. Smithsonian scientists monitor the release of every animal via satellite tracking collars. The tracking collars provide data on oryx movements and survival, as well as a means for tracking and monitoring individuals on the ground through radio telemetry.

Artificial insemination helps zoos and conservation breeding facilities with limited space maximize genetic diversity and minimize the number of animals needing to be transported, which can be costly and potentially stressful for the animal. In 2017, SCBI scientists developed an alternate protocol for inseminating scimitar-horned oryx where animal handling takes place in a hydraulic restraint device without the need for anesthesia. In June 2018, there was a successful birth using this modified approach.

The revised CO-Synch protocol included three hormone injections over nine days leading up to the non-surgical artificial inseminations in November 2020. Esmerelda and Leanne were artificially inseminated using frozen-thawed semen collected from two different male oryx ranked in the top 45 of male oryx in the Association of Zoos and Aquariums Species Survival Plan. The samples were originally collected 20 and 13 years ago.

SCBI plays a leading role in the Smithsonians global efforts to save wildlife species from extinction and train future generations of conservationists. SCBI spearheads research programs at its headquarters in Front Royal, Virginia, the Smithsonians National Zoo in Washington, D.C., and at field research stations and training sites worldwide. SCBI scientists tackle some of todays most complex conservation challenges by applying and sharing what they learn about animal behavior and reproduction, ecology, genetics, migration and conservation sustainability.

# # #

See the article here:
Two Scimitar-Horned Oryx Calves Born as Result of Artificial Insemination at Smithsonian Conservation Biology Institute - Smithsonian's National Zoo...

Queen of Dancehall Spice had a stellar opening week for her new album 10 to say the least. With rave reviews from various outlets (including ours) plus billboards in Times Square, Spice has been over the moon about the response and the only place left for her to go wasup.

The acrobatic deejay takes on an intergalactic space mission to find the perfect male specimen in her latest video, Send It Up. Hilarious antics ensue (with cameos from comedians World Dawg and Slick Whiteline) but Spice didnt come to play, as the old, young and well-endowed see how they measure up with the waistline warrior Queen.

Many have lauded the transportive quality of Spices debut LP: a nostalgic medley of booming 90s dancehall with EDM, R&B and Afropop nudges and an overall inventive cadence. For her fourth music video from the suite, the Inches singer took fans light-years away with a cinematic concept on the sexually charged track. With only ten men left in the universe, Spice must find the chosen one to repopulate the planet Zariah.

Mi cyaan live without man so me ah go find him, Spice says upon receiving her mission and spends the clip fashionably fulfilling her duty.

In the Jay Will directed visuals, Spice reaffirms yet another of 10s track titles: Size Matters. The QOD and her team of experts aboard Starship Spice busily test genetics, waistlines and fitness as Spice lays down the credentials.

One f mi gi yuh, we nuh haffi romantic/ Me ah gyal weh like when di sittn gigantic, Spice declares in the first verse, a lyric that was also quoted by rap queen Nicki Minaj, when she hailed Send It Up as her favorite track on the album.

Even amongst stars and planets, Spice brings her dancehall A game with a Magnum Tonic Wine to power through the mission. After all the raunchy dance moves and lab work, however, the cinematic clip ends in suspense and we never get to see Spices cosmic Prince Charming.

She does leave us a clue though, as an unseen character in a spacesuit makes his way towards the lab and it seems we might be in for a follow-up soon.

10 is clearly the Genie deejays magic number nearly 200K viewers have sent the mini-movie to Top 10 Youtube trending in mere hours. Most weighed in on its cinematic style, while others praised the QOD for taking traditional dancehall to a new frontier.

All hail the Queen SPICEthis video is out of this world. . literally. Absolutely love it, you are blessed beyond measure. Nuff Love and Respect, one fan wrote while another praised the blue haired divas golden touch, Queen, you delivered once again, you have the midas touch, anything you touch is just golden. Once again well done.

Press play on the Send It Up visuals above.

Read more:
Spice Goes On Intergalactic Mission In Cinematic Visuals For Send It Up: Watch - DancehallMag

About 30,000 years ago, when enormous mammoths and woolly rhinos roamed the Northern Hemisphere, a tiny cave lion cub with golden-brown fur took her final stroll through the Siberian tundra.

Disaster struck suddenly perhaps a mudslide, or a crack splitting open the permafrost underfoot and the cub fell. Buried in ice, she was quickly mummified; today, her fur, skin, organs and teeth remain almost exactly as they appeared on the day of her death, thousands of years ago.

Scientists named this ill-fated cub Sparta, after mammoth tusk hunters discovered her fossilized remains poking out of the melting permafrost of Yakutia, Siberia, in 2017. Along with Boris a male cave lion cub discovered just 50 feet (15 meters) away in 2018 Sparta is the subject of an extensive new study published Aug. 4 in the journal Quaternary, in which scientists examined the anatomy of the extinct cats in unprecedented detail.

"Sparta is probably the best-preserved ice age animal ever found, and is more or less undamaged apart from the fur being a bit ruffled," study co-author Love Daln, a genetics professor at the Centre for Palaeogenetics in Stockholm, Sweden, told CNN.com. "She even had the whiskers preserved."

Cave lions (Panthera spelaea) are close relatives of modern African lions. They lived widely across the Northern Hemisphere during the last ice age (the chilly epoch that spanned from approximately 2.1 million to 11,600 years ago). Unlike their modern cousins, these large cats adapted to extremely harsh conditions, including freezing winds and long, cold winters marked by continuous nights.

According to the new study, Boris and Sparta didn't get much of a chance to test their mettle against the perils of the ice age. Through a variety of methods including radiocarbon dating, X-ray imaging and partial DNA sequencing, the researchers learned that the two cubs were approximately 1 to 2 months old when they died, with their sharp frontal teeth just beginning to emerge.

Although the cubs' remains were discovered a stone's throw away from each other, their deaths were separated by tens of thousands of years. A radiocarbon analysis of the cubs' skin, hair and muscle showed that Sparta died approximately 28,000 years ago, while Boris met his end more than 43,000 years ago. This finding suggests that the area was probably "attractive to cave lions for making dens, but it was probably also susceptible to them collapsing," the researchers wrote in the study.

X-ray scans of the cubs' bones seem to support a collapse scenario. Both cubs showed skull damage, dislocated ribs and other small "distortions" in their skeletons that could have been caused by "the earth's mass pressure," the researchers wrote. Further distortions likely occurred after the cubs were already buried, as the surrounding permafrost turned their bodies into furry mummies.

For all their injuries, the cubs didn't show any markings indicative of a predator attack, the team added.

At the moment, there's little more that can be learned about how the cubs died but further research could help reveal how they lived. In future studies, the researchers hope to completely sequence Boris and Sparta's DNA, which could put the evolutionary history of cave lions in a broader context and reveal some of their unique genetic features.

Originally published on Live Science.

Read the original post:
Frozen mummy of extinct cave lion is 'best-preserved ice age animal ever found,' researchers say - Livescience.com